How much funding has Alethia Biotherapeutics raised?

Alethia Biotherapeutics has raised $16.5M in total funding, most recently a Series C round.

Who are Alethia Biotherapeutics's investors?

Alethia Biotherapeutics's investors include BDC Venture Capital.

When was Alethia Biotherapeutics founded?

Alethia Biotherapeutics was founded in 2002.

Where is Alethia Biotherapeutics headquartered?

Alethia Biotherapeutics is headquartered in Montreal, Canada.

What industry is Alethia Biotherapeutics in?

Alethia Biotherapeutics operates in Biotech.

How many employees does Alethia Biotherapeutics have?

Alethia Biotherapeutics has 11-50 employees.

Alethia Biotherapeutics

Montreal, Canada · Founded 2002 · $16.5M raised

Biotech

Headquarters: Montreal
Employees: 11–50
Founded: 2002
Business Model: B2B

Website: alethiabio.com
Total Funding: $16.5M
Last Round: $4.7M Series COct 2024
Rounds: 5

About

Alethia Biotherapeutics is a privately held, Montreal-based clinical-stage biotechnology company founded in 2002. The company is engaged in the discovery and development of therapeutic monoclonal antibodies against novel, clinically relevant targets in cancer and inflammatory diseases, with a focus on cancer-associated epithelial-to-mesenchymal transition (EMT) pathways.

Summary

Alethia Biotherapeutics is a Biotech company based in Montreal, Canada, founded in 2002. It has raised $16.5M in total across 5 rounds, most recently a $4.7M Series C round in Oct 2024. Investors include BDC Venture Capital.